Advertisement

Immunogenicity of Therapeutic Proteins

  • Wim JiskootEmail author
  • Theo Rispens
  • Grzegorz Kijanka
Chapter

Abstract

The use of proteins for medical applications has revolutionized therapies of many diseases/disorders that were often incurable with small-molecule medicines. However, since the first use of proteins as medicines, their immunogenicity has been a major problem. Over the years the quality and safety of therapeutic protein products have improved dramatically. Nevertheless, even the protein medicines of the newest generation may still cause adverse immunological events, posing a safety risk for patients and/or compromising their efficacy. Immunogenicity of therapeutic proteins is a complex, multifactorial phenomenon. In this chapter we summarize the current knowledge about immune mechanisms underlying the immunogenicity of therapeutic proteins and discuss influencing factors and clinical consequences of protein immunogenicity as well as strategies for immunogenicity assessment and mitigation.

Keywords

Aggregation Anti-drug antibodies (ADA) Formulation Immunogenicity Neutralizing antibodies Tolerance 

References

  1. Aledort L (1994) Inhibitors in hemophilia patients: current status and management. Am J Hematol 47:208–217CrossRefGoogle Scholar
  2. Antonelli G, Dianzani F (1999) Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10:413–422PubMedGoogle Scholar
  3. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448–1451CrossRefGoogle Scholar
  4. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity. Clin Immunol 118:42–50CrossRefGoogle Scholar
  5. Barnard JG, Babcock K, Carpenter JF (2013) Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci 102:915–928CrossRefGoogle Scholar
  6. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1468CrossRefGoogle Scholar
  7. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P (2004) Immunogenicity of interferon beta: differences among products. J Neurol 251:II15–II24CrossRefGoogle Scholar
  8. Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S (2015) Immunogenicity to infliximab is associated with HLA-DRB1. Gut 64:1344–1345CrossRefGoogle Scholar
  9. Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T (2015) Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 418:29–38CrossRefGoogle Scholar
  10. Brandse JF, Mathôt RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, Rietdijk S, Löwenberg M, Ponsioen CY, Singh S, van den Brink GR, D’Haens GR (2016) Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 14:251–258CrossRefGoogle Scholar
  11. Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W (2013) Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30:1719–1728CrossRefGoogle Scholar
  12. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475CrossRefGoogle Scholar
  13. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 358:1109–1117CrossRefGoogle Scholar
  14. Cousens L, Najafian N, Martin WD, De Groot AS (2014) Tregitope: immunomodulation powerhouse. Hum Immunol 75:1139–1146CrossRefGoogle Scholar
  15. de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU (2015) Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediat Inflamm 2015:1–11CrossRefGoogle Scholar
  16. Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26:167–172CrossRefGoogle Scholar
  17. Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, Lindholm A, Broderick E, Francke S, Wu X, Colaianne J, Cohen N (2008) Case–control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics 9:157–167CrossRefGoogle Scholar
  18. Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR 3rd, Lowe J, Maia M, Wong T (2011) Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal 54:351–358CrossRefGoogle Scholar
  19. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28:625–652CrossRefGoogle Scholar
  20. Food and Drug Administration (2002) Adalimumab. 2002. Pharmacology reviews: adalimumab product approval information—licensing action. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm. Accessed 4 Nov 2017
  21. Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, Xue L (2016) Pre-existing antibody: biotherapeutic modality-based review. AAPS J 18:311–320CrossRefGoogle Scholar
  22. Griswold KE, Bailey-Kellogg C (2016) Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol 39:79–88CrossRefGoogle Scholar
  23. Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V (2017) Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci 106:2946–2954CrossRefGoogle Scholar
  24. Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777CrossRefGoogle Scholar
  25. Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The Immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265CrossRefGoogle Scholar
  26. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897–903CrossRefGoogle Scholar
  27. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS (2013) T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol 149:534–555CrossRefGoogle Scholar
  28. Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, Joubert MK, Jawa V, Narhi LO (2016) Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci 105:1567–1575CrossRefGoogle Scholar
  29. Kijanka G, Jiskoot W, Sauerborn M, Schellekens H, Brinks V (2012) Immunogenicity of therapeutic proteins in pharmaceutical formulation development of peptides and proteins. CRC Press, Boca Raton, pp 297–322Google Scholar
  30. Krishna M, Palme H, Duo J, Lin Z, Corbett M, Dodge R, Piccoli S, Myler H, Pillutla R, Desilva B (2015) Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples. Bioanalysis 7:1869–1883CrossRefGoogle Scholar
  31. Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866–1884CrossRefGoogle Scholar
  32. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939CrossRefGoogle Scholar
  33. Malucchi S, Bertolotto A (2008) Clinical aspects of immunogenicity to biopharmaceuticals. Immunog Biopharm 47:27–56CrossRefGoogle Scholar
  34. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16CrossRefGoogle Scholar
  35. Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691–697CrossRefGoogle Scholar
  36. Moss AC, Brinks V, Carpenter JF (2013) Review article: Immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther 38:1188–1197CrossRefGoogle Scholar
  37. Oldenburg J, Lacroix-Desmazes S, Lillicrap D (2015) Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating Factor VIII immunogenicity. Haematologica 100:149–156CrossRefGoogle Scholar
  38. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P (2001) Interferon-beta (INF-Beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56–61PubMedGoogle Scholar
  39. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S (2009) The association of anti-R-HuEpo-associated pure Red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant 24:1545–1549CrossRefGoogle Scholar
  40. Prümmer O (1997) Treatment-induced antibodies to interleukin-2. Biotherapy 10:15–24CrossRefGoogle Scholar
  41. Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following sc administration. AAPS J 14:559–570CrossRefGoogle Scholar
  42. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose Frequency, and route of administration. Ann Neurol 48:706–712CrossRefGoogle Scholar
  43. Rougeot C, Marchand PM, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R (1991) Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 35:76–81CrossRefGoogle Scholar
  44. Ryff JC (1997) Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interf Cytokine Res 17:S29–S33Google Scholar
  45. Schellekens H (2002a) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462CrossRefGoogle Scholar
  46. Schellekens H (2002b) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740CrossRefGoogle Scholar
  47. Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:II4–II9CrossRefGoogle Scholar
  48. Schellekens H, Jiskoot W (2006) Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 3:123–130CrossRefGoogle Scholar
  49. Schellekens H, Hennink WE, Brinks V (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 30:1729–1734CrossRefGoogle Scholar
  50. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281CrossRefGoogle Scholar
  51. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J 16:658–673CrossRefGoogle Scholar
  52. Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354–387CrossRefGoogle Scholar
  53. van Beers MM, Jiskoot W, Schellekens H (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interf Cytokine Res 30:767–775CrossRefGoogle Scholar
  54. van de Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108:962–971CrossRefGoogle Scholar
  55. van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015a) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74:311–314CrossRefGoogle Scholar
  56. van Schie KA, Wolbink GJ, Rispens T (2015b) Cross-reactive and pre-existing antibodies to therapeutic antibodies. Effects on treatment and immunogenicity. MAbs 7:662–671CrossRefGoogle Scholar
  57. van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T (2017) Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the Antigen-binding site. J Allergy Clin Immunol 139:1035–1037CrossRefGoogle Scholar
  58. van Schouwenburg PA, Rispens T, Wolbink GJ (2013a) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9:164–172CrossRefGoogle Scholar
  59. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013b) Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 72:1680–1686CrossRefGoogle Scholar
  60. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADA) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72:165–178CrossRefGoogle Scholar
  61. Weigle WO (1971) Recent observations and concepts in immunological unresponsiveness and autoimmunity. Clin Exp Immunol 9:437–447PubMedPubMedCentralGoogle Scholar
  62. Xue L, Rup B (2013) Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J 15:893–896CrossRefGoogle Scholar

Suggested Reading

  1. Brinks V, Jiskoot W, Schellekens H (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28:2379–2385CrossRefGoogle Scholar
  2. Filipe V, Hawe A, Schellekens H, Jiskoot W (2010) Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Robert C (eds) Aggregation of therapeutic proteins. Wiley, HobokenCrossRefGoogle Scholar
  3. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2007) Immunogenicity of therapeutic proteins. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. Wiley, Hoboken, pp 911–931Google Scholar
  4. Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM (2016) Immunogenicity of therapeutic protein aggregates. J Pharm Sci 105:417–430CrossRefGoogle Scholar
  5. Schellekens H, Crommelin D, Jiskoot W (2007) Immunogenicity of antibody therapeutics. In: Dübel S (ed) Handbook of therapeutic antibodies. Wiley, Weinheim, pp 267–276CrossRefGoogle Scholar
  6. Schellekens H (2010) The immunogenicity of therapeutic proteins. Discov Med 9:560–564PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR)Leiden UniversityLeidenThe Netherlands
  2. 2.Department of ImmunopathologySanquinAmsterdamThe Netherlands

Personalised recommendations